Disposition of pirprofen, a new anti-inflammatory drug.

Plasma and urine concentrations of 2-(3-chloro-4[3-pyrrolinyl]phenyl) propionic acid, pirprofen, a new nonsteroidal anti-inflammatory compound, are described for normal male volunteers receiving one or more doses of the drug. Orally administered pirprofen is rapidly and almost completely absorbed from the gastrointestinal tract, resulting in maximum plasma levels in 1 to 2 hr. Mean peak levels are 23 microng/ml after an oral pirprofen dose of 200 mg; lower doses given proportionally lower levels.

A dual approach to the evaluation of the efficacy of a new rheumatoid arthritic agent--pirprofen.

Pirprofen was compared to placebo in a double-blind crossover study in 12 rheumatoid arthritis patients. Two approaches--univariate and multivariate--were used to analyze the study results which were in the form of arithmetic changes from pretreatment levels of six efficacy measurements. The univariate analysis failed to permit a single decision to be made regarding the further investigation and use of pirprofen in rheumatoid arthritis.

Acetylsecohemicholinium: chemical and pharmacological evaluation of an open-ring hemicholinium.

Acetylsecohemicholinium No. 3 (AcHC-3), the acetate of the open ring (seco form of hemicholinium No. 3, HC-3) hydrolyzes in vitro to the hemiacetal HC-3 at pH values above 9, a temperature-dependent conversion illustrated by ultraviolet spectral shifts from 305 to 257 mmu, and to a limited extent by certain esterases as measured by manometric analysis.